John W. Mcconnell
Expertise in
12
conditions

Dr. John W. Mcconnell

Pulmonary Medicine
100 West Market Street, Suite 2, 
Louisville, KY 
Accepting New Patients
44 Years of Experience
Expertise in
12
conditions
100 West Market Street, Suite 2, 
Louisville, KY 

Overview

John Mcconnell is a Pulmonary Medicine provider practicing medicine in Louisville, Kentucky. He has been practicing medicine for over 44 years.

Dr. Mcconnell is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Lung Metastases, Gastrostomy, and Endoscopy.

Dr. Mcconnell is board certified in American Board Of Internal Medicine, Pulmonary Disease - 1992 and American Board Of Internal Medicine, Internal Medicine - 1986. He is actively involved in clinical research, co-authoring 19 peer reviewed articles and participating in 16 clinical trials. Dr. Mcconnell is currently accepting new patients.

Graduate Year

1982

Specialties

Pulmonary Medicine

Licenses

Internal Medicine in KY

Board Certifications

American Board Of Internal Medicine, Pulmonary Disease - 1992
American Board Of Internal Medicine, Internal Medicine - 1986

Fellowships

University of Kentucky Medical Center, Pulmonary Disease, 1988

Hospital Affiliations

Norton Hospitals, Inc
Norton Clark Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Norton Pulmonary Specialists
100 West Market Street, Suite 2, Louisville, KY 40202

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Completed
Publish Date: June 16, 2026
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Completed
Publish Date: June 10, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension
A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drug: Rodatristat Ethyl
Study Phase: Phase 2
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Completed
Publish Date: December 11, 2023
Intervention Type: Drug, Other
Study Drug: ND-L02-s0201
Study Phase: Phase 2
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Enrollment Status: Terminated
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: Inhaled treprostinil solution
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD
Enrollment Status: Terminated
Publish Date: July 27, 2023
Intervention Type: Combination product
Study Drug: INOpulse
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Enrollment Status: Completed
Publish Date: June 02, 2022
Intervention Type: Drug
Study Drug: UT-15C
Study Phase: Phase 3
View 9 Less Clinical Trials

19 Total Publications

Setting expectations with oral selexipag: an expert consensus-based approach on best practices to initiate, dose, titrate, and manage side effects (SEs) in patients with pulmonary arterial hypertension (PAH).
Setting expectations with oral selexipag: an expert consensus-based approach on best practices to initiate, dose, titrate, and manage side effects (SEs) in patients with pulmonary arterial hypertension (PAH).
Journal: Pulmonary pharmacology & therapeutics
Published: September 30, 2025
Similar Doctors
Expertise in
45
conditions
Dr. Mark E. Esterle
Pulmonary Medicine
Expertise in
45
conditions
Dr. Mark E. Esterle
Pulmonary Medicine
Referral may be required
Before you request

Louisville Pulmonary Care PLLC

4003 Kresge Way Ste 312, 
Louisville, KY 
 (5.3 miles away)
502-899-7377
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Esterle is a Pulmonary Medicine provider practicing medicine in Louisville, Kentucky. Dr. Esterle is highly rated in 45 conditions, according to our data. His clinical expertise encompasses Lung Metastases, Pneumonia, Chronic Obstructive Pulmonary Disease (COPD), Gastrostomy, and Endoscopy. Dr. Esterle is currently accepting new patients.

Expertise in
33
conditions
Dr. Azmi Draw
Pulmonary Medicine
Expertise in
33
conditions
Dr. Azmi Draw
Pulmonary Medicine
Referral may be required

Kelli G Applegate MD LLC

727 Mount Tabor Rd Ste B, 
New Albany, IN 
 (6.3 miles away)
812-913-6040
Languages Spoken:
English, Arabic, Arabic - Jordanian
See accepted insurances
Accepting New Patients

Azmi Draw is a Pulmonary Medicine provider practicing medicine in New Albany, Indiana. Dr. Draw is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Obstructive Sleep Apnea, Lung Metastases, Pneumonia, Gastrostomy, and Advanced Bronchoscopy. Dr. Draw is currently accepting new patients.

Expertise in
21
conditions
Dr. Moutaz Al-Nabhan
Pulmonary Medicine
Expertise in
21
conditions
Dr. Moutaz Al-Nabhan
Pulmonary Medicine
Referral may be required
Before you request

Functional Imaging And Assessment Of Kentucky PSC

1015 DuPont Rd, 
Louisville, KY 
 (6.6 miles away)
502-883-0227
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Moutaz Al-Nabhan is a Pulmonary Medicine provider practicing medicine in Louisville, Kentucky. Dr. Al-Nabhan is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Lung Metastases, Pneumonia, Chronic Obstructive Pulmonary Disease (COPD), Gastrostomy, and Endoscopy. Dr. Al-Nabhan is currently accepting new patients.

Frequently Asked Questions about Dr. John W. Mcconnell

How do I make an appointment with Dr. John W. Mcconnell?

You can book an appointment with Dr. John W. Mcconnell by calling their office at 502-587-8000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. John W. Mcconnell a top-rated expert for Pulmonary Hypertension?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. John W. Mcconnell is classified as an Elite expert for Pulmonary Hypertension, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. John W. Mcconnell specialize in?

While Dr. John W. Mcconnell is a Pulmonary Medicine, they have specific expertise in Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, and Lung Metastases. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pulmonary Medicine.

Does Dr. John W. Mcconnell participate in research or clinical trials?

Yes. Dr. John W. Mcconnell has published 19 articles and abstracts on conditions like Pulmonary Hypertension. You can view a list of Dr. John W. Mcconnell's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. John W. Mcconnell accept my insurance?

Dr. John W. Mcconnell accepts most major insurance plans, including Aetna and Ambetter. We recommend calling the office directly at 502-587-8000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mcconnell's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 41 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile